Chemomab Therapeutics Ltd ADR Dossier
|
SectorHealth Care IndustryBiotechnology Beta (adjusted)0.78 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $1.30Price as of 1 Oct 2026 Data confidenceNot applicable Market Cap $9.5M Enterprise Value $2M Shares Outstanding 7.3M diluted Next Earnings Date15 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Chemomab Therapeutics is a high-conviction, clinical-stage biotechnology play focused on its lead asset, nebokitug (CM-101), a first-in-class monoclonal antibody neutralizing CCL24. Following positive Phase 2 SPRING trial results in Primary Sclerosing Cholangitis (PSC) and successful alignment with the FDA on a streamlined Phase 3 regulatory pathway, the company is positioned to potentially deliver the first disease-modifying therapy for PSC. While the current microcap valuation reflects market concerns over cash runway and potential dilution, the robust clinical data and active strategic partnering discussions present a highly asymmetric risk-reward profile. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$5.00 Mean target$5.00 High · most bullish analyst$5.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $5.0020% Partnering discussions stall, forcing Chemomab to execute a highly dilutive recapitalization or toxic financing round to fund the Phase 3 trial. Alternatively, the Phase 3 trial experiences severe enrollment delays or fails to show a statistically significant impact on clinical events, resulting in a near-total loss of asset value. Base CaseCentral scenario $15.0050% Chemomab executes a regional or territorial licensing deal that extends its cash runway through the initiation of the Phase 3 PSC trial. The company begins Phase 3 enrollment with moderate dilution from supplementary equity raises, while clinical progress and pipeline milestones in systemic sclerosis (SSc) drive steady valuation recovery toward historical averages. Bull CaseUpside scenario $25.0030% Chemomab secures a high-value global strategic partnership with a major pharmaceutical company, providing substantial upfront cash that fully funds the Phase 3 PSC trial and eliminates dilution risk. The Phase 3 trial successfully meets its primary composite clinical event endpoint, leading to rapid FDA approval and first-to-market commercialization in a multi-billion dollar market with no approved therapies. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |